A multinational, prospective, two-arm, observational study to collect real-world data on joint and bone health in patients receiving prophylaxis with simoctocog alfa or emicizumab in routine clinical practice
Latest Information Update: 25 Jan 2024
At a glance
- Drugs Emicizumab (Primary) ; Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms PROVE
Most Recent Events
- 25 Jan 2024 New trial record
- 09 Dec 2023 According to the trial design presented at 65th American Society of Hematology Annual Meeting and Exposition, an interim analysis is planned after 2 years.
- 09 Dec 2023 Trial design presented at 65th American Society of Hematology Annual Meeting and Exposition.